{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:07:11Z","timestamp":1791407231552,"version":"4.3.3"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ygyno.2010.06.003","type":"journal-article","created":{"date-parts":[[2010,8,8]],"date-time":"2010-08-08T08:37:25Z","timestamp":1281256645000},"page":"7-17","source":"Crossref","is-referenced-by-count":125,"title":["SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance"],"prefix":"10.1016","volume":"119","author":[{"given":"John O.","family":"Schorge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah D.","family":"Kauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.06.003_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynaecological cancer: the size of the problem","volume":"20","author":"Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.06.003_bib3","doi-asserted-by":"crossref","DOI":"10.3322\/caac.20073","article-title":"Cancer Statistics 2010","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.06.003_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nm1230","article-title":"Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract","volume":"11","author":"Cheng","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/er.22.2.255","article-title":"Ovarian surface epithelium: biology, endocrinology, and pathology","volume":"22","author":"Auersperg","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ygyno.2010.06.003_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","article-title":"Early events in the pathogenesis of epithelial ovarian cancer","volume":"26","author":"Landen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1470-2045(08)70308-5","article-title":"The cell of origin of ovarian epithelial tumours","volume":"9","author":"Dubeau","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib9","first-page":"490","article-title":"Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum","volume":"55","author":"Muto","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.06.003_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jnci\/90.11.841","article-title":"Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations","volume":"90","author":"Schorge","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib11","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/gyno.2001.6430","article-title":"BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a gynecologic oncology group study","volume":"83","author":"Smith","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.10927","article-title":"Ovulation and risk of epithelial ovarian cancer","volume":"104","author":"Purdie","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/89.13.932","article-title":"Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer","volume":"89","author":"Schildkraut","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1054\/bjoc.2000.1596","article-title":"Menstrual and reproductive factors in relation to ovarian cancer risk","volume":"84","author":"Titus-Ernstoff","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/aje\/kwm157","article-title":"Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk","volume":"166","author":"Tworoger","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/aje\/kwh315","article-title":"A case\u2013control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs","volume":"160","author":"Rossing","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib18","doi-asserted-by":"crossref","first-page":"b249","DOI":"10.1136\/bmj.b249","article-title":"Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study","volume":"338","author":"Jensen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2010.06.003_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ygyno.2006.02.025","article-title":"Incidence of ovarian cancer of grand multiparous women \u2014 a population-based study in finland","volume":"103","author":"Hinkula","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.EDE.0000050701.99792.95","article-title":"Does pregnancy induce the shedding of premalignant ovarian cells?","volume":"14","author":"Rostgaard","year":"2003","journal-title":"Epidemiology"},{"key":"10.1016\/j.ygyno.2010.06.003_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0090-8258(03)00088-X","article-title":"Risk factors for ovarian cancer in taiwan: a case\u2013control study in a low-incidence population","volume":"89","author":"Yen","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.06.003_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/jnci\/djj375","article-title":"Menopausal hormone therapy and ovarian cancer risk in the national institutes of health-AARP diet and health study cohort","volume":"98","author":"Lacey","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib24","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1158\/1055-9965.EPI-07-0550","article-title":"Menopausal hormone therapy and risk of epithelial ovarian cancer","volume":"16","author":"Rossing","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2010.06.003_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/09513590701483910","article-title":"An analysis of ovarian cancer in the million women study","volume":"23","author":"Neves-E-Castro","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10552-008-9125-x","article-title":"Hormone therapy and ovarian cancer: incidence and survival","volume":"19","author":"Wernli","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2010.06.003_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2005.02.007","article-title":"Ovarian cancer incidence in the United States, 1992\u20131999","volume":"97","author":"Quirk","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib28","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/cncr.11349","article-title":"Incidence of ovarian cancer by race and ethnicity in the United States, 1992\u20131997","volume":"97","author":"Goodman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/85.2.142","article-title":"Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case\u2013control studies. epithelial ovarian cancer in black women. Collaborative ovarian cancer group","volume":"85","author":"John","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib30","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.270.23.2813","article-title":"Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study","volume":"270","author":"Hankinson","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.06.003_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00001648-200003000-00006","article-title":"Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer","volume":"11","author":"Ness","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.ygyno.2010.06.003_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10552-005-5383-z","article-title":"Dietary risk factors for ovarian cancer: the Adventist Health Study (United States)","volume":"17","author":"Kiani","year":"2006","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2010.06.003_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.6004\/jnccn.2006.0016","article-title":"Genetic\/familial high-risk assessment: breast and ovarian","volume":"4","author":"Daly","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ygyno.2010.06.003_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2005.03.6772","article-title":"Characterization of BRCA1 and BRCA2 mutations in a large United States sample","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib35","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin\u2013cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2010.06.003_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","article-title":"Cancer risk in mutation carriers of DNA-mismatch-repair genes","volume":"81","author":"Aarnio","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/hmg\/6.1.105","article-title":"Cancer risk associated with germline DNA mismatch repair gene mutations","volume":"6","author":"Dunlop","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ygyno.2010.06.003_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","article-title":"Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","volume":"107","author":"Lancaster","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","article-title":"Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO","volume":"94","author":"Euhus","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1200\/JCO.2005.01.9737","article-title":"Optimal selection of individuals for BRCA mutation testing: a comparison of available methods","volume":"24","author":"James","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/0003-4819-147-7-200710020-00002","article-title":"Validity of models for predicting BRCA1 and BRCA2 mutations","volume":"147","author":"Parmigiani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib43","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1200\/JCO.2005.07.013","article-title":"Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation","volume":"23","author":"Gomez-Garcia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","article-title":"Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.06.003_bib45","first-page":"193","article-title":"ACOG practice bulletin. Prophylactic oophorectomy. number 7, September 1999 (replaces technical bulletin number 111, December 1987). Clinical management guidelines for obstetrician\u2013gynecologists. American College of Obstetricians and Gynecologists","volume":"67","author":"[Anonymous]","year":"1999","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ygyno.2010.06.003_bib46","first-page":"3776","article-title":"Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"8","author":"Satagopan","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.06.003_bib47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2010.06.003_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ygyno.2005.05.002","article-title":"Society of Gynecologic Oncologists Clinical Practice Committee statement on prophylactic salpingo-oophorectomy","volume":"98","author":"[Anonymous]","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.06.003_bib51","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","article-title":"Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy","volume":"18","author":"Lu","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib52","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib53","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib55","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib56","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2003.12.009","article-title":"Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis","volume":"92","author":"Karlan","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib57","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1525-1438.2003.t01-1-13050.x","article-title":"Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum","volume":"13","author":"Skates","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib58","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group Study","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2010.06.003_bib59","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","article-title":"Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers","volume":"23","author":"Kramer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMoa052627","article-title":"Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome","volume":"354","author":"Schmeler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib61","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.296.12.1507","article-title":"Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: a systematic review","volume":"296","author":"Lindor","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.06.003_bib62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.6004\/jnccn.2006.0034","article-title":"Current approaches in familial colorectal cancer: a clinical perspective","volume":"4","author":"Lynch","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ygyno.2010.06.003_bib63","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1200\/JCO.2004.07.179","article-title":"Biology of epithelial ovarian cancer: implications for screening women at high genetic risk","volume":"22","author":"Hogg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib64","doi-asserted-by":"crossref","first-page":"e1000114","DOI":"10.1371\/journal.pmed.1000114","article-title":"The preclinical natural history of serous ovarian cancer: defining the target for early detection","volume":"6","author":"Brown","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib65","unstructured":"National Cancer Institute Ovarian Cancer Screening (PDQ). http:\/\/www.cancer.gov\/cancertopics\/pdq\/screening\/ovarian\/HealthProfessional\/page2."},{"key":"10.1016\/j.ygyno.2010.06.003_bib66","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z","article-title":"Ovarian carcinoma diagnosis","volume":"89","author":"Goff","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib67","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/00006250-200612000-00060","article-title":"ACOG committee opinion no. 356: routine cancer screening","volume":"108","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0029-7844(01)01457-0","article-title":"Symptoms of ovarian cancer","volume":"98","author":"Olson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib69","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.06.003_bib70","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ygyno.2006.06.032","article-title":"Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study","volume":"103","author":"Bosse","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib71","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib72","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib73","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1200\/JCO.2005.05.097","article-title":"Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system","volume":"23","author":"Stirling","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.22371","article-title":"Development of an ovarian cancer symptom index: possibilities for earlier detection","volume":"109","author":"Goff","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib75","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cncr.23577","article-title":"Combining a symptoms index with CA 125 to improve detection of ovarian cancer","volume":"113","author":"Andersen","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1471-0528.2006.01153.x","article-title":"Feasibility of screening for ovarian cancer using symptoms as selection criteria","volume":"114","author":"Rufford","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2010.06.003_bib77","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/cncr.24407","article-title":"The search for meaning-symptoms and transvaginal sonography screening for ovarian cancer: predicting malignancy","volume":"115","author":"Pavlik","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0090-8258(03)00292-0","article-title":"Importance of the general practitioner in the early detection of ovarian cancer","volume":"90","author":"Petignat","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2008.05.006","article-title":"The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial","volume":"110","author":"Johnson","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib80","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1093\/clinchem\/39.12.2509","article-title":"Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum","volume":"39","author":"Kenemans","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.ygyno.2010.06.003_bib81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.06.003_bib82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.2910420507","article-title":"Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer","volume":"42","author":"Zurawski","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib83","doi-asserted-by":"crossref","first-page":"206s","DOI":"10.1200\/JCO.2003.02.955","article-title":"Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women","volume":"21","author":"Skates","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib84","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1200\/JCO.2005.01.6642","article-title":"Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer","volume":"23","author":"Menon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib86","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/gyno.2002.6865","article-title":"The role of the generalist obstetrician\u2013gynecologist in the early detection of ovarian cancer","volume":"87","author":"ACOG Committee on Gynecologic Practice","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib87","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jama.269.9.1123","article-title":"Prospective study of serum CA-125 levels as markers of ovarian cancer","volume":"269","author":"Helzlsouer","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.06.003_bib88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0090-8258(03)00414-1","article-title":"Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and doppler flow sonography","volume":"91","author":"Ueland","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib89","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/cncr.22594","article-title":"Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened","volume":"109","author":"van Nagell","year":"2007","journal-title":"Cancer"},{"issue":"1214","key":"10.1016\/j.ygyno.2010.06.003_bib90","first-page":"21","article-title":"The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer","volume":"192","author":"Fishman","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib91","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.bjc.6603015","article-title":"Surveillance of women at high risk for hereditary ovarian cancer is inefficient","volume":"94","author":"Oei","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2006.10.044","article-title":"Factors associated with return for routine annual screening in an ovarian cancer screening program","volume":"104","author":"Andrykowski","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib93","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ajog.2005.05.005","article-title":"Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial","volume":"193","author":"Buys","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib94","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","article-title":"Results from four rounds of ovarian cancer screening in a randomized trial","volume":"113","author":"Partridge","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/djp438","article-title":"Assessing lead time of selected ovarian cancer biomarkers: a nested case\u2013control study","volume":"102","author":"Anderson","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.06.003_bib96","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/1078-0432.CCR-07-1569","article-title":"Diagnostic markers for early detection of ovarian cancer","volume":"14","author":"Visintin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.06.003_bib97","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"Mor","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2010.06.003_bib98","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.06.003_bib99","unstructured":"SGO statment regarding OvaSure. http:\/\/sgo.org\/WorkArea\/showcontent.aspx?id=1754."},{"key":"10.1016\/j.ygyno.2010.06.003_bib100","unstructured":"SGO Statement Regarding OvaCheck. http:\/\/sgo.org\/WorkArea\/showcontent.aspx?id=954."},{"key":"10.1016\/j.ygyno.2010.06.003_bib101","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.2006.09.7543","article-title":"The quest for ovarian cancer's holy grail: can CA-125 still be the chalice of early detection?","volume":"25","author":"Karlan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib102","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.ygyno.2010.06.003_bib103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/gyno.2000.5811","article-title":"Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors","volume":"78","author":"Engelen","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib104","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1525-1438.2007.01146.x","article-title":"Retrospective multicenter study of a clinicopathologic analysis of pseudomyxoma peritonei associated with ovarian tumors (KGOG 3005)","volume":"18","author":"Lee","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.06.003_bib105","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1200\/JCO.2005.02.2582","article-title":"Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range","volume":"23","author":"Santillan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0020-7292(96)02721-X","article-title":"Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer","volume":"54","author":"Sugiyama","year":"1996","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ygyno.2010.06.003_bib107","article-title":"CA 125, PET alone, PET\u2013CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","author":"Gu","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib108","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","author":"Simcock","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography (FDG-PET\/CT) in recurrent ovarian cancer","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib110","first-page":"912","article-title":"Ovarian cancer. Clinical practice guidelines in oncology","volume":"4","author":"Morgan","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ygyno.2010.06.003_bib111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0305-7372(95)90002-0","article-title":"Tumor markers in the management of patients with ovarian cancer","volume":"21","author":"Tuxen","year":"1995","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2010.06.003_bib112","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.annonc.a057754","article-title":"The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer","volume":"1","author":"van der Burg","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib113","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2009.27.18_suppl.1","article-title":"A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05\/EORTC 55955 trials)","volume":"27","author":"Rustin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2010.06.003_bib114","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.06.003_bib115","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-03-0365","article-title":"Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer","volume":"10","author":"Schorge","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.06.003_bib116","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1055-9965.EPI-06-0681","article-title":"Pooling of case specimens to create standard serum sets for screening cancer biomarkers","volume":"16","author":"Skates","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810004300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810004300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T03:59:26Z","timestamp":1591761566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810004300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0090825810004300"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.06.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}